543 related articles for article (PubMed ID: 16001399)
1. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
2. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice.
Yu XX; Murray SF; Watts L; Booten SL; Tokorcheck J; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E436-45. PubMed ID: 18523126
[TBL] [Abstract][Full Text] [Related]
3. Reduced adiposity and improved insulin sensitivity in obese mice with antisense suppression of 4E-BP2 expression.
Yu XX; Pandey SK; Booten SL; Murray SF; Monia BP; Bhanot S
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E530-9. PubMed ID: 18198353
[TBL] [Abstract][Full Text] [Related]
4. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Choi CS; Savage DB; Kulkarni A; Yu XX; Liu ZX; Morino K; Kim S; Distefano A; Samuel VT; Neschen S; Zhang D; Wang A; Zhang XM; Kahn M; Cline GW; Pandey SK; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Biol Chem; 2007 Aug; 282(31):22678-88. PubMed ID: 17526931
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
6. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
7. Coordinated alteration of hepatic gene expression in fatty acid and triglyceride synthesis in LCAT-null mice is associated with altered PUFA metabolism.
Song H; Zhu L; Picardo CM; Maguire G; Leung V; Connelly PW; Ng DS
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E17-E25. PubMed ID: 16105858
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
Liu Y; Millar JS; Cromley DA; Graham M; Crooke R; Billheimer JT; Rader DJ
Biochim Biophys Acta; 2008 Mar; 1781(3):97-104. PubMed ID: 18252207
[TBL] [Abstract][Full Text] [Related]
9. Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6J-Lep(ob/ob) mice.
Kim HJ; Lee KT; Park YB; Jeon SM; Choi MS
Mol Nutr Food Res; 2008 Aug; 52(8):965-73. PubMed ID: 18481331
[TBL] [Abstract][Full Text] [Related]
10. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
11. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
12. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice.
Frederico MJ; Vitto MF; Cesconetto PA; Engelmann J; De Souza DR; Luz G; Pinho RA; Ropelle ER; Cintra DE; De Souza CT
Scand J Gastroenterol; 2011 Nov; 46(11):1381-8. PubMed ID: 21936721
[TBL] [Abstract][Full Text] [Related]
13. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
14. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice.
Liang Y; Osborne MC; Monia BP; Bhanot S; Watts LM; She P; DeCarlo SO; Chen X; Demarest K
Metabolism; 2005 Jul; 54(7):848-55. PubMed ID: 15988691
[TBL] [Abstract][Full Text] [Related]
16. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
[TBL] [Abstract][Full Text] [Related]
17. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Choi SS; Diehl AM
Curr Opin Lipidol; 2008 Jun; 19(3):295-300. PubMed ID: 18460922
[TBL] [Abstract][Full Text] [Related]
18. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
[TBL] [Abstract][Full Text] [Related]
20. The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans.
Kantartzis K; Machicao F; Machann J; Schick F; Fritsche A; Häring HU; Stefan N
Clin Sci (Lond); 2009 Mar; 116(6):531-7. PubMed ID: 18980578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
